Conduction System Pacing With INGEVITY+

NCT06014866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1383

Last updated 2025-05-23

No results posted yet for this study

Summary

The study is intended to evaluate the safety and effectiveness of the Boston Scientific INGEVITY+ cardiac pacing lead when implanted in the left bundle branch area (LBBA).

Conditions

  • Bradycardia

Interventions

DEVICE

Cardiac pacing

Patient's previously implanted with the INGEVITY+ lead located in the LBBA

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY
  • Duke University

    lead OTHER

Principal Investigators

  • Daniel Friedman, MD · Duke University

Eligibility

Min Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2024-08-27
Completion
2024-08-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014866 on ClinicalTrials.gov